“The Most Growth, At The Cheapest Price”
What are the most affordable biopharmaceutical growth stocks in the S&P 500 right now? Or, as today’s article puts it, which biopharma stocks in the… Read More »“The Most Growth, At The Cheapest Price”
What are the most affordable biopharmaceutical growth stocks in the S&P 500 right now? Or, as today’s article puts it, which biopharma stocks in the… Read More »“The Most Growth, At The Cheapest Price”
Why might the stock highlighted in today’s article – shares of which have more than tripled investors’ money over the past year – be the… Read More »3 Reasons This Could Be “The Best Biotech Stock You Can Buy At The Moment”
When it comes to the five biotech penny stocks to watch this quarter highlighted in today’s article, the author emphasizes that “These aren’t just names… Read More »There’s Good Reason To Watch These 5 Biotech Penny Stocks This Quarter
While large-cap biotech stocks may come with less risk than their small-cap counterparts, the author of today’s article notes that “On the plus side small-cap… Read More »10 Under $10: The Best Small-Cap Biotech Stocks For 2021
Among the three biotech stocks to watch going forward in 2021 highlighted by the author of today’s article is a specialty company focused on developing… Read More »3 Biotech Stocks To Watch – Including A Pioneering CBD Company
When it comes to investing in biotech stocks, the author of today’s article points out that “By identifying companies that are likely to report rapid… Read More »On The Cusp Of Commercializing Its First Drug, Now May Be The Time To Buy This Biotech Stock
The final week of January was yet another big one for biotech, with perhaps the most important development of the week being phase III trial results for Novavax’s COVID-19 vaccine.
The genomic revolution in underway, with the author of today’s article noting that “artificial intelligence is converging with decades of breakthrough genomics research to create a new generation of hyper-efficient, hyper-accurate, and hyper-precise gene editing medicines.”
As January comes to a close, which biotech stocks await FDA decisions in February that could serve as catalysts?
When it comes to the performance of healthcare companies during the pandemic, the author of today’s article notes that “Those best prepared for developing a… Read More »This Biotech Laggard Could Offer Traders A Market-Beating Opportunity